[go: up one dir, main page]

WO2015195863A8 - 2-((4s)-6-(4-chlorophényl)-1-méthyl-4h-benzo[c]isoxazolo[4,5-e]azépine-4-yl)acétamide hydraté - Google Patents

2-((4s)-6-(4-chlorophényl)-1-méthyl-4h-benzo[c]isoxazolo[4,5-e]azépine-4-yl)acétamide hydraté Download PDF

Info

Publication number
WO2015195863A8
WO2015195863A8 PCT/US2015/036348 US2015036348W WO2015195863A8 WO 2015195863 A8 WO2015195863 A8 WO 2015195863A8 US 2015036348 W US2015036348 W US 2015036348W WO 2015195863 A8 WO2015195863 A8 WO 2015195863A8
Authority
WO
WIPO (PCT)
Prior art keywords
isoxazolo
azepin
acetamide
chlorophenyl
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/036348
Other languages
English (en)
Other versions
WO2015195863A1 (fr
Inventor
Michael L. Hall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Constellation Pharmaceuticals Inc
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of WO2015195863A1 publication Critical patent/WO2015195863A1/fr
Publication of WO2015195863A8 publication Critical patent/WO2015195863A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des formes hydratées de 2-((4S)-6-(4-chlorophényl)-l-méthyl-4 H-benzo[c]isoxazolo [4,5-e] azépine-4-yl) acétamide, qui sont utiles en tant qu'inhibiteurs de protéines contenant des bromodomaines. L'invention concerne également des compositions pharmaceutiquement acceptables comprenant ces formes hydratées, ainsi que des procédés d'utilisation de ces compositions dans le traitement de divers troubles.
PCT/US2015/036348 2014-06-20 2015-06-18 2-((4s)-6-(4-chlorophényl)-1-méthyl-4h-benzo[c]isoxazolo[4,5-e]azépine-4-yl)acétamide hydraté Ceased WO2015195863A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462014785P 2014-06-20 2014-06-20
US62/014,785 2014-06-20

Publications (2)

Publication Number Publication Date
WO2015195863A1 WO2015195863A1 (fr) 2015-12-23
WO2015195863A8 true WO2015195863A8 (fr) 2016-03-03

Family

ID=53488483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/036348 Ceased WO2015195863A1 (fr) 2014-06-20 2015-06-18 2-((4s)-6-(4-chlorophényl)-1-méthyl-4h-benzo[c]isoxazolo[4,5-e]azépine-4-yl)acétamide hydraté

Country Status (1)

Country Link
WO (1) WO2015195863A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
HK1249058A1 (zh) 2015-03-18 2018-10-26 Arvinas, Inc. 用於增强靶向蛋白质降解的化合物和方法
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
EP3577109A4 (fr) 2017-01-31 2020-11-18 Arvinas Operations, Inc. Ligands de céréblon et composés bifonctionnels les contenant
EP3743066A4 (fr) 2018-01-26 2021-09-08 Yale University Modulateurs de protéolyse à base d'imide et procédés d'utilisation associés
EP3774772A1 (fr) 2018-04-13 2021-02-17 Arvinas Operations, Inc. Ligands de céréblon et composés bifonctionnels les contenant
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN118660892A (zh) 2022-01-31 2024-09-17 星座制药公司 2-((4s)-6-(4-氯苯基)-1-甲基-4h-苯并[c]异噁唑并[4,5-e]氮杂卓-4-基)乙酰胺的无水结晶形式
WO2025049555A1 (fr) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions et procédés d'inhibition et de dégradation ciblées de protéines dans une cellule d'insecte

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
TWI602820B (zh) * 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途

Also Published As

Publication number Publication date
WO2015195863A1 (fr) 2015-12-23

Similar Documents

Publication Publication Date Title
WO2015195862A8 (fr) Formes cristallines de l'acétamide 2-((4s)-6- (4-chlorophényl)-1-méthyl-4 h-benzo [c] isoxazolo [4s5-e] azépin-4-yle)
WO2015195863A8 (fr) 2-((4s)-6-(4-chlorophényl)-1-méthyl-4h-benzo[c]isoxazolo[4,5-e]azépine-4-yl)acétamide hydraté
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
HUE053704T2 (hu) 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére
EP3481402A4 (fr) Composés, compositions et méthodes de traitement de maladie
WO2014152029A3 (fr) Composés d'oxazolo[5,4-c] quinolin-2-one en tant qu'inhibiteurs de bromodomaines
IL246564A (en) 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
EP3177366A4 (fr) Combinaisons d'inhibiteurs de tyrosine kinase de bruton et leurs utilisations
WO2016034591A3 (fr) Pores mutants
EP3215511A4 (fr) Pyrazolo(1,5-a)pyrimidines substituées et leur utilisation dans le traitement de troubles médicaux
WO2016004305A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2015001504A3 (fr) Formulations d'anticorps et procédés correspondants
EP3484504A4 (fr) Composés, compositions et méthodes de traitement de maladie
PH12016500866A1 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
HK1206726A1 (en) Imidazotriazinone compounds
EP3321271A4 (fr) Procédé de production de dérivé de 7h-pyrollo[2,3-d]pyrimidine et intermédiaire correspondant
WO2016073771A3 (fr) Dérivés de pyrrolopyrimidine utilisés en tant qu'inhibiteurs de la kinase mps1/ttk
EP3328380A4 (fr) Combinaisons d'inhibiteur de la tyrosine kinase de bruton et leurs utilisations
MX379439B (es) Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1-metilciclohexano-1-carboxamida y métodos para utilizarlas.
HK1225994A1 (zh) 用於治疗过敏性病症的组合物
WO2017042198A3 (fr) Agents et procédés d'utilisation de ceux-ci pour la prévention et le traitement de troubles musculaires liés aux cellules souches
WO2016197042A8 (fr) Formulations à libération modifiée ou ciblée de linaclotide
WO2016069542A3 (fr) Composés de lactone, leurs procédés de préparation et d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15731817

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15731817

Country of ref document: EP

Kind code of ref document: A1